產(chǎn)品說明
可溶性環(huán)氧化物水解酶（sEH）抑制劑
該產(chǎn)品包含在以下化合物庫中:
質(zhì)量控制
化學(xué)性質(zhì)
| CAS號 | 479413-68-8 | ? | ? |
| 別名 |
| 分子式 | C19H36N2O3 | 分子量 | 340.5 |
| 溶解性 | Soluble in DMSO | 儲存條件 | Store at -20° |
?
實(shí)驗(yàn)操作
| 細(xì)胞實(shí)驗(yàn)[2]： |
| 細(xì)胞系 | |
| 溶解方法 | |
| 反應(yīng)時間 | |
| 應(yīng)用 | |
| 動物實(shí)驗(yàn)[3]： |
| 動物模型 | |
| 劑量 | |
| 注意事項(xiàng) | |
| References: |
產(chǎn)品描述
IC50: 11.1 and 112 nM for the mouse and human soluble epoxide hydrolase, respectively
CUDA is a soluble epoxide hydrolase (sEH) inhibitor.
Epoxyeicosatrienoic acid metabolites of arachidonic acid, such as 11(12)-EET and 14(15)-EET, have been identified as endothelium derived hyperpolarizing factors with vasodilator activity. Soluble epoxide hydrolase (sEH) can catalyze the conversion of EETs to the corresponding dihydroxy eicosatrienoic acids thereby diminishing their activity.
In vitro: In a previous study, in order to test if the CUDA’s mechanism of action is retained upon structural modification, the dissociation constants of CUDA was evaluated for mouse sEH. Results showed that for CUDA, competitive a tight-binding inhibition kinetic was obtained with r2 > 0.99. Moreover, the KI value of 3.8 nM was obtained for CUDA. In addition, it was found that CUDA was an inhibitor of sEH exhibiting IC50 values of 11.1 nM and 112 nM for the mouse and human enzymes, respectively [1].
In vivo: Currently, there is no animal in vivo data reported.
Clinical trial: So far, no clinical study has been conducted.
Reference:
[1] C.? Morisseau, M. H. Goodrow, J. W. Newman, et al. Structural refinement of inhibitors of urea-based soluble epoxide hydrolases. Biochemical Pharmacology 63, 1599-1608 (2002).
溫馨提示：不可用于臨床治療。